vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and INNOVATIVE INDUSTRIAL PROPERTIES INC (IIPR). Click either name above to swap in a different company.

INNOVATIVE INDUSTRIAL PROPERTIES INC is the larger business by last-quarter revenue ($66.7M vs $37.2M, roughly 1.8× GYRE THERAPEUTICS, INC.). INNOVATIVE INDUSTRIAL PROPERTIES INC runs the higher net margin — 47.8% vs -3.7%, a 51.4% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -13.1%). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs -6.0%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

Oxford Properties is a Canadian multinational corporation, with operations in real estate investment, development and property management. Its portfolio includes office, retail, industrial, multi-residential, life sciences and hotel assets. Established privately in 1960 and later wholly owned by the Ontario Municipal Employees Retirement System (OMERS) since 2003, the company is headquartered in Toronto with regional head offices in New York City, London, Australia, Singapore and Luxembourg. ...

GYRE vs IIPR — Head-to-Head

Bigger by revenue
IIPR
IIPR
1.8× larger
IIPR
$66.7M
$37.2M
GYRE
Growing faster (revenue YoY)
GYRE
GYRE
+46.6% gap
GYRE
33.4%
-13.1%
IIPR
Higher net margin
IIPR
IIPR
51.4% more per $
IIPR
47.8%
-3.7%
GYRE
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
-6.0%
IIPR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GYRE
GYRE
IIPR
IIPR
Revenue
$37.2M
$66.7M
Net Profit
$-1.4M
$31.8M
Gross Margin
95.3%
Operating Margin
0.3%
47.8%
Net Margin
-3.7%
47.8%
Revenue YoY
33.4%
-13.1%
Net Profit YoY
-340.1%
-20.4%
EPS (diluted)
$-0.01
$1.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
IIPR
IIPR
Q4 25
$37.2M
$66.7M
Q3 25
$30.6M
$64.7M
Q2 25
$26.8M
$62.9M
Q1 25
$22.1M
$71.7M
Q4 24
$27.9M
$76.7M
Q3 24
$25.5M
$76.5M
Q2 24
$25.2M
$79.8M
Q1 24
$27.2M
$75.5M
Net Profit
GYRE
GYRE
IIPR
IIPR
Q4 25
$-1.4M
$31.8M
Q3 25
$5.9M
$29.3M
Q2 25
$1.6M
$26.0M
Q1 25
$3.7M
$31.1M
Q4 24
$569.0K
$40.0M
Q3 24
$2.9M
$40.2M
Q2 24
$4.5M
$42.0M
Q1 24
$9.9M
$39.4M
Gross Margin
GYRE
GYRE
IIPR
IIPR
Q4 25
95.3%
Q3 25
94.7%
Q2 25
95.7%
Q1 25
95.9%
Q4 24
95.8%
Q3 24
96.2%
Q2 24
96.9%
Q1 24
96.4%
Operating Margin
GYRE
GYRE
IIPR
IIPR
Q4 25
0.3%
47.8%
Q3 25
22.7%
45.5%
Q2 25
8.1%
45.9%
Q1 25
10.3%
47.4%
Q4 24
2.4%
54.7%
Q3 24
16.6%
54.8%
Q2 24
12.7%
53.1%
Q1 24
29.7%
55.7%
Net Margin
GYRE
GYRE
IIPR
IIPR
Q4 25
-3.7%
47.8%
Q3 25
19.4%
45.3%
Q2 25
5.9%
41.4%
Q1 25
16.9%
43.3%
Q4 24
2.0%
52.2%
Q3 24
11.2%
52.6%
Q2 24
18.0%
52.6%
Q1 24
36.6%
52.3%
EPS (diluted)
GYRE
GYRE
IIPR
IIPR
Q4 25
$-0.01
$1.07
Q3 25
$0.03
$0.97
Q2 25
$0.00
$0.86
Q1 25
$0.00
$1.03
Q4 24
$0.00
$1.35
Q3 24
$0.01
$1.37
Q2 24
$0.01
$1.44
Q1 24
$0.03
$1.36

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
IIPR
IIPR
Cash + ST InvestmentsLiquidity on hand
$52.4M
$47.6M
Total DebtLower is stronger
$393.7M
Stockholders' EquityBook value
$106.0M
$1.8B
Total Assets
$166.1M
$2.4B
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
IIPR
IIPR
Q4 25
$52.4M
$47.6M
Q3 25
$60.0M
$41.9M
Q2 25
$54.4M
$104.9M
Q1 25
$29.9M
$133.3M
Q4 24
$26.7M
$151.2M
Q3 24
$25.1M
$172.4M
Q2 24
$25.1M
$160.9M
Q1 24
$37.4M
$173.5M
Total Debt
GYRE
GYRE
IIPR
IIPR
Q4 25
$393.7M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
GYRE
GYRE
IIPR
IIPR
Q4 25
$106.0M
$1.8B
Q3 25
$101.9M
$1.9B
Q2 25
$92.0M
$1.9B
Q1 25
$68.1M
$1.9B
Q4 24
$63.3M
$1.9B
Q3 24
$63.2M
$1.9B
Q2 24
$60.4M
$1.9B
Q1 24
$56.6M
$2.0B
Total Assets
GYRE
GYRE
IIPR
IIPR
Q4 25
$166.1M
$2.4B
Q3 25
$159.4M
$2.3B
Q2 25
$152.6M
$2.3B
Q1 25
$129.8M
$2.4B
Q4 24
$125.4M
$2.4B
Q3 24
$125.2M
$2.4B
Q2 24
$120.9M
$2.4B
Q1 24
$122.0M
$2.4B
Debt / Equity
GYRE
GYRE
IIPR
IIPR
Q4 25
0.21×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
IIPR
IIPR
Operating Cash FlowLast quarter
$-5.6M
$198.2M
Free Cash FlowOCF − Capex
$-5.8M
FCF MarginFCF / Revenue
-15.5%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
6.22×
TTM Free Cash FlowTrailing 4 quarters
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
IIPR
IIPR
Q4 25
$-5.6M
$198.2M
Q3 25
$4.7M
$45.6M
Q2 25
$2.1M
$48.4M
Q1 25
$-129.0K
$54.2M
Q4 24
$-2.8M
$258.4M
Q3 24
$1.7M
$64.9M
Q2 24
$-5.5M
$64.2M
Q1 24
$2.9M
$71.6M
Free Cash Flow
GYRE
GYRE
IIPR
IIPR
Q4 25
$-5.8M
Q3 25
$4.0M
Q2 25
$1.8M
Q1 25
$-251.0K
Q4 24
$-2.8M
Q3 24
$1.0M
Q2 24
$-6.9M
Q1 24
$2.7M
FCF Margin
GYRE
GYRE
IIPR
IIPR
Q4 25
-15.5%
Q3 25
13.1%
Q2 25
6.8%
Q1 25
-1.1%
Q4 24
-10.1%
Q3 24
4.1%
Q2 24
-27.5%
Q1 24
9.8%
Capex Intensity
GYRE
GYRE
IIPR
IIPR
Q4 25
0.4%
Q3 25
2.2%
Q2 25
1.0%
Q1 25
0.6%
Q4 24
0.2%
Q3 24
2.7%
Q2 24
5.8%
Q1 24
0.9%
Cash Conversion
GYRE
GYRE
IIPR
IIPR
Q4 25
6.22×
Q3 25
0.79×
1.56×
Q2 25
1.32×
1.86×
Q1 25
-0.03×
1.75×
Q4 24
-4.85×
6.46×
Q3 24
0.60×
1.61×
Q2 24
-1.21×
1.53×
Q1 24
0.29×
1.82×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons